Skip to content
The Nexus
HEALTHJun 4 · 10:30 UTCSTAT NEWSAdam Feuerstein

STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?

Revolution Medicines' pancreatic cancer drug daraxonrasib is poised for FDA approval after showing promise in metastatic cases post-chemotherapy. The drug's potential expansion to newly diagnosed metastatic patients is under discussion following its positive reception at the ASCO plenary session.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
Revolution MedicinesorganizationdaraxonrasibtopicFood and Drug Administrationorganizationmetastatic pancreatic cancertopicASCO plenary sessiontopicSTAT+organization
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting